It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...

GLP-1 weight loss users cut food spending in their first 3 months, says Circana. But by the end of year one, spending is ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 weeks in adults with overweight or obesity and without diabetes, according ...

January is often a time for setting health goals, with weight loss topping many New Year’s resolutions. As people explore the best path forward, they may encounter a variety of ...

McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effi ...

BOSTON – A Massachusetts nutritionist has advice for anyone working on having a better diet in 2025. She says rather than restricting what you eat, focus on ways to improve your gut. Gut health has ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...